Astria Therapeutics, Inc. (ATXS)
Automate Your Wheel Strategy on ATXS
With Tiblio's Option Bot, you can configure your own wheel strategy including ATXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATXS
- Rev/Share 0.0
- Book/Share 4.4912
- PB 2.712
- Debt/Equity 0.0183
- CurrentRatio 14.8851
- ROIC -0.4954
- MktCap 687377009.0
- FreeCF/Share -2.0
- PFCF -5.925
- PE -6.0426
- Debt/Assets 0.0169
- DivYield 0
- ROE -0.3863
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | ATXS | H.C. Wainwright | -- | Buy | $16 | $20 | Sept. 17, 2025 |
| Initiation | ATXS | Cantor Fitzgerald | -- | Overweight | -- | $47 | April 29, 2025 |
| Initiation | ATXS | JMP Securities | -- | Mkt Outperform | -- | $26 | Jan. 31, 2025 |
News
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Published: October 17, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determ.
Read More
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
Read More
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Published: October 14, 2025 by: Benzinga
Sentiment: Positive
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.
Read More
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Published: October 14, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Oct. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with BioCryst. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present one poster and one oral presentation at the 2025 HAEi Regional Conference EMEA, taking place October 10-12, 2025 in Rome, Italy. Dr. William Lumry, M.D., ARA Research Center, Dallas, TX, United States of America, will share information on the global Phase 3 trial of navenibart in a.
Read More
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal antibody antagonist of OX40, in healthy subjects. STAR-0310 demonstrated a best-in-class half-life of up to 68 days, consistent with administration every six months, durable cytokine inhibition, and was we.
Read More
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 294.8% upside potential for Astria Therapeutics (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Thursday, September 4 at 3:20pm ET. A webcast of the presentation can be accessed at the following link: https://sqps.onstreamsecure.com/origin/enliven/players/E.
Read More
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Astria Therapeutics (ATXS) points to a 333.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
Published: June 06, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FRCPC, FAAAAI, Managing Director and Chair, Ottawa Allergy Research Corporation, will present combined i.
Read More
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025. Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from.
Read More
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the Eastern Allergy Conference (EAC) in Palm Beach, Florida on May 30, 2025. Raffi Tachdjian, M.D., Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, L.
Read More
Astria Therapeutics: A High-Conviction Bet On HAE
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation.
Read More
About Astria Therapeutics, Inc. (ATXS)
- IPO Date 2015-06-25
- Website https://www.astriatx.com
- Industry Biotechnology
- CEO Jill C. Milne
- Employees 78